Atherosclerosis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Regeneron, Sanofi, Immunitor, Novartis, MedImmune, Cerenis Therapeutics, AFFiRiS, VBL Therapeutics, other

May 18 04:54 2021
Atherosclerosis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Regeneron, Sanofi, Immunitor, Novartis, MedImmune, Cerenis Therapeutics, AFFiRiS, VBL Therapeutics, other

Atherosclerosis Pipeline

Atherosclerosis is a slow, lifelong progression of changes in the blood vessels that may start in childhood and get worse faster with the age. Atherosclerosis usually doesn’t cause any symptoms until blood supply to an organ is reduced. When this happens, symptoms vary, depending on the specific organ involved: Heart — Symptoms include the chest pain of angina and shortness of breath, sweating, nausea, dizziness or light-headedness, breathlessness or palpitations. Brain — When atherosclerosis narrows brain arteries, it can cause dizziness or confusion; weakness or paralysis on one side of the body. Abdomen — When atherosclerosis narrows the arteries to the intestines, there may be dull or cramping pain in the middle of the abdomen. There is no cure for atherosclerosis, but treatment can slow or halt the worsening of the disease. The major treatment goal is to prevent significant narrowing of the arteries so that symptoms never develop and vital organs are never damaged.

DelveInsight’s, “Atherosclerosis Pipeline Insight, 2021” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Atherosclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 


Some of Atherosclerosis Companies are:

  • Regeneron/Sanofi
  • Immunitor
  • Novartis
  • MedImmune
  • Cerenis Therapeutics
  • AFFiRiS
  • VBL Therapeutics
  • Abcentra
  • Millennium Pharmaceuticals
  • Daiichi Sankyo
  • Band Therapeutic
  • Innomedica
  • Chugai Pharmaceutical
  • Repair Biotechnologies
  • Northstar  medical radioisotopes
  • Entos therapeutics
  • Caladrius Biosciences
  • Novo Nordisk
  • Esperion Therapeutics
  • Immusoft Corp
  • Kaleido Biosciences
  • Takeda Pharmaceutical
  • MetrioPharm
  • And Many Others


Request for Free Sample Report:


DelveInsight’s Atherosclerosis report covers around 25+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates


Some of Atherosclerosis Therapies are:

  • Alirocumab
  • Tofogliflozin
  • VB 201
  • atherosclerosis vaccine
  • ATH 04
  • BT 200
  • actinium-225/bismuth-213
  • Inclisiran
  • CLBS12
  • CER-001
  • Plozalizumab
  • Canakinumab
  • DS 8190
  • MEDI6012
  • Orticumab
  • Forskolin/rolipram liposomal
  • And Many Others


Request for Free Sample Report:


Current Atherosclerosis Treatment Scenario and Atherosclerosis Emerging Therapies:

  • How many companies are developing Atherosclerosis drugs?
  • How many Atherosclerosis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atherosclerosis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Atherosclerosis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Atherosclerosis and their status?
  • What are the key designations that have been granted to the emerging drugs?


Request for Free Sample Report:


Table of Contents:


Executive Summary

Atherosclerosis: Overview

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

Atherosclerosis – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

Atherosclerosis Collaboration Deals

Late Stage Products (Regsitered)

• Comparative Analysis

Aloricumab: Sanofi/ Regeneron

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

• Comparative Analysis

VB 201: VBL therapeutics

Drug profiles in the detailed report…..

Early stage products (Phase I)

• Comparative Analysis

BT 200: Band Therapeutics

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

Atherosclerosis Key Companies

Atherosclerosis Key Products

Atherosclerosis- Unmet Needs

Atherosclerosis- Market Drivers and Barriers

Atherosclerosis- Future Perspectives and Conclusion

Atherosclerosis Analyst Views

Atherosclerosis Key Companies


Request for Detailed TOC:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States